Ultrasound-triggered therapeutic microbubbles enhance the efficacy of cytotoxic drugs by increasing circulation and tumor drug accumulation and limiting bioavailability and toxicity in normal tissues

Citation for published version:
Ingram, N, McVeigh, LE, Abou-Saleh, RH, Maynard, J, Peyman, SA, McLaughlan, JR, Fairclough, M, Marston, G, Valleley, EMA, Jimenez-Macias, JL, Charalambous, A, Townley, W, Haddrick, M, Wierzbicki, A, Wright, A, Volpato, M, Simpson, PB, Treanor, DE, Thomson, NH, Loadman, PM, Bushby, RJ, Johnson, BRG, Jones, PF, Evans, JA, Freear, S, Markham, AF, Evans, SD & Coletta, PL 2020, ‘Ultrasound-triggered therapeutic microbubbles enhance the efficacy of cytotoxic drugs by increasing circulation and tumor drug accumulation and limiting bioavailability and toxicity in normal tissues’, Theranostics, vol. 10, no. 24, pp. 10973-10992. https://doi.org/10.7150/thno.49670

Digital Object Identifier (DOI):
10.7150/thno.49670

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher’s PDF, also known as Version of record

Published In:
Theranostics

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Ultrasound-triggered therapeutic microbubbles enhance
the efficacy of cytotoxic drugs by increasing circulation and
tumor drug accumulation and limiting bioavailability and
toxicity in normal tissues

Nicola Ingram1, Laura E. McVeigh1*, Radwa H. Abou-Saleh2,3, Juliana Maynard4, Sally A. Peyman2, James R.
McLaughlan5, Michael Fairclough6, Gemma Marston1, Elizabeth M. A. Valleley1, Jorge L. Jimenez-Macias1,
Antonia Charalambous1, William Townley4, Malcolm Haddrick4, Antonia Wierzbicki7, Alexander Wright1,
Milène Volpato1, Peter B. Simpson4, Darren E. Treanor1, Neil H. Thomson8, Paul M. Loadman7, Richard J.
Bushby2,9, Benjamin R.G. Johnson2, Pamela F. Jones1, J. Anthony Evans1, Steven Freear5, Alexander F. Markham1,
Stephen D. Evans2,7* and P. Louise Coletta1*.

1. Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James’s University Hospital, Leeds, LS9 7TF, United Kingdom.
2. Molecular and Nanoscale Physics Group, School of Physics and Astronomy, University of Leeds, LS2 9JT, United Kingdom.
3. Department of Physics, Faculty of Science, Mansoura University, Egypt.
4. Medicines Discovery Catapult, Mereside, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.
5. Faculty of Electronic and Electrical Engineering, University of Leeds, LS2 9JT, United Kingdom.
6. Wolfson Molecular Imaging Centre, University of Manchester, Palatine Road, Manchester, M20 3LI United Kingdom.
7. Institute of Cancer Therapeutics, University of Bradford, BD7 1DP, United Kingdom.
8. School of Dentistry, Wellcome Trust Brenner Building, St. James’s University Hospital, Leeds, LS9 7TF, United Kingdom.
9. School of Chemistry, University of Leeds, Leeds, LS2 9JT, United Kingdom.

*These authors contributed equally to this work.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2020.06.18; Accepted: 2020.08.14; Published: 2020.09.01

Abstract

Most cancer patients receive chemotherapy at some stage of their treatment which makes improving the
efficacy of cytotoxic drugs an ongoing and important goal. Despite large numbers of potent anti-cancer agents
being developed, a major obstacle to clinical translation remains the inability to deliver therapeutic doses to a
tumor without causing intolerable side effects. To address this problem, there has been intense interest in
nanoformulations and targeted delivery to improve cancer outcomes. The aim of this work was to demonstrate
how vascular endothelial growth factor receptor 2 (VEGFR2)-targeted, ultrasound-triggered delivery with
therapeutic microbubbles (thMBs) could improve the therapeutic range of cytotoxic drugs.

Methods: Using a microfluidic microbubble production platform, we generated thMBs comprising
VEGFR2-targeted microbubbles with attached liposomal payloads for localised ultrasound-triggered delivery of
irinotecan and SN38 in mouse models of colorectal cancer. Intravenous injection into tumor-bearing mice was
used to examine targeting efficiency and tumor pharmacodynamics. High-frequency ultrasound and
bioluminescent imaging were used to visualise microbubbles in real-time. Tandem mass spectrometry
(LC-MS/MS) was used to quantify intratumoral drug delivery and tissue biodistribution. Finally, 89Zr PET
radiotracing was used to compare biodistribution and tumor accumulation of ultrasound-triggered SN38
thMBs with VEGFR2-targeted SN38 liposomes alone.

Results: ThMBs specifically bound VEGFR2 in vitro and significantly improved tumor responses to low dose
irinotecan and SN38 in human colorectal cancer xenografts. An ultrasound trigger was essential to achieve the
selective effects of thMBs as without it, thMBs failed to extend intratumoral drug delivery or demonstrate
enhanced tumor responses. Sensitive LC-MS/MS quantification of drugs and their metabolites demonstrated
that thMBs extended drug exposure in tumors but limited exposure in healthy tissues, not exposed to
ultrasound, by persistent encapsulation of drug prior to elimination. 89Zr PET radiotracing showed that the
percentage injected dose in tumors achieved with thMBs was twice that of VEGFR2-targeted SN38 liposomes
alone.
Conclusions: thMBs provide a generic platform for the targeted, ultrasound-triggered delivery of cytotoxic drugs by enhancing tumor responses to low dose drug delivery via combined effects on circulation, tumor drug accumulation and exposure and altered metabolism in normal tissues.

Key words: Microbubble; ultrasound; VEGFR2; nanoformulation; colorectal cancer

Introduction

A major obstacle to improving cancer outcomes is effective tumor-targeted drug delivery with minimum off-site toxicity. Despite large numbers of anti-cancer drugs being developed, their clinical use is often precluded by poor efficacy, intolerable side-effects and/or drug resistance.

Advanced drug delivery systems developed to overcome these problems, such as liposomes and nanoparticles (NPs), have not yet demonstrated widespread clinical impact. A recent count showed 50 different NPs currently in clinical trials but only 2 were FDA/EMA approved from 2016-2019 [1]. This is due, in part, to a lack of clear pharmacological evidence of improved efficacy compared with conventional drug delivery and a lack of understanding of the mechanisms by which NP formulations elicit their response. For example, a recent meticulous study showed in multiple tumor types that active transport may be required [2]. Using ‘Zombie’ mice, these researchers showed that active uptake of NPs via transendothelial pathways was predominant, potentially warranting a shift to active tumor targeting and away from the reliance on passive mechanisms involving enhanced permeability and retention (EPR) [2, 3]. However, multiple mechanisms including active targeting, EPR and transcytosis [4] could all potentially contribute to effective uptake. Nevertheless, the role of active targeting via antibodies or ligands, is a major area of research in “EPR and beyond” [5] aimed at increasing NP uptake into tumors [6-9]. In addition, little understanding of the absorption, distribution, metabolism, excretion and toxicity (ADMET) as well as inadequate tumor accumulation have proved challenging for nanodrug and nanoparticle therapeutics, thus precluding the use of more potent and highly toxic drugs in nanoformulations [10, 11].

To address some of these problems, several actively targeted and triggered systems are being developed where multiplexed particles and external energetic triggers (ultrasound [US], heat, light) or intrinsic tumor triggers (pH, redox) combine for tumor-specific drug delivery [12]. This combination approach to anti-cancer drug targeting may provide the required improvement in cancer outcomes with improved quality-of-life using existing or future agents. This is of particular significance when considering cancer incidence and demographics where for example in colorectal cancer (CRC), incidence is strongly related to age and rises steeply from 50-54 years with the highest rates seen in the 85–89 age group [13], a group projected to almost double over the next 25 years [14]. This population may therefore be more suited to less invasive, low dose or adaptive therapies that control rather than cure cancer.

Microbubbles (MBs) are micron-sized gas-filled phospholipid-shelled spheres, clinically approved for contrast-enhanced US imaging, which also show promise as vehicles for drug delivery [15-17]. The first use of MBs for improving tumor drug delivery was via co-injection with free drug with the application of low-intensity US to facilitate drug uptake by “sonoporation”, the formation of pores due to the biomechanical response to oscillating MBs [18-20]. Indeed this method has been examined in several clinical trials [21, 22] with some encouraging partial responses in both hepatic metastases and inoperable pancreatic cancer in early Phase I trials. However, more recent pre-clinical studies suggest that the most effective drug delivery by MBs is mediated by liposomes attached to the MB shell [23-25]. In this way, US-induced oscillation or collapse of the MB can affect local release and delivery of drug into the target tissue [26]. Furthermore, recently described mathematical and single bubble models [27] using fluorescently labelled, targeted MBs bound at a surface, identified physical mechanisms of drug release and transport following US exposure which may involve acoustic streaming, a phenomenon known to be generated by an oscillating bubble close to a border or wall [28].

Due to their micron size, MBs are intra-vascular agents; therefore actively targeting tumor endothelial markers (such as VEGFR2 or αvβ3 integrin) have been used to enhance the imaging of tumor vasculature [29-31] and also to target liposomes [10, 11, 32]. VEGFR2 lends itself to this role as it is upregulated in most solid tumors, including CRC [33, 34]. Smith et al. showed that VEGFR2 (and VEGFR3) was widespread in vessels of malignant tissues of the colon, breast and lung compared with matched normal controls [34]. VEGF/VEGFR2 blockade has also proved effective in treating advanced metastatic CRC [35]. Molecular imaging with VEGFR2 targeted MBs has been used
for monitoring therapy effects in an experimental CRC model [36] and clinically for breast, ovarian, prostate [37, 38] and renal cell cancer imaging [39] demonstrating widespread potential for VEGFR2 in cancer imaging and targeting.

Irinotecan ([1,4’-Bipiperidine]-1’-carboxylic acid, CPT-11) is a chemotherapy drug used in primary and secondary line treatment of CRC (FDA approval given in 1998). Irinotecan is a prodrug, requiring activation by carboxylesterases to form SN38 (7-Ethyl-10-hydroxy-camptothecin), its active metabolite which is up to 1000 times more toxic. SN38 is detoxified by the polymorphic enzyme UGT1A1 to SN38 glucuronide (SN38G) [40]. Only a fraction of the administered irinotecan dose is converted to SN38, with the remaining drug being metabolized by CYP3A4 (and possibly CYP3A5) or excreted via hepatic or renal transport [40, 41]. SN38 causes cell death by inhibiting topoisomerase I (Topo I), an enzyme vital to DNA replication and transcription [40, 42]. This induces irreversible double-strand breaks and subsequently cell death in proliferating cells. Although SN38 shows in vitro efficacy as an anti-cancer agent, it is extremely hydrophobic and the fact that it cannot be dissolved in any pharmaceutically acceptable solvent has precluded its direct use.

We have previously developed a flexible microfluidic MB production platform [43] that allows on-chip assembly of therapeutic MBs (thMBs) (see Figure 1A for schematic) of defined size and lifetime [44] and showed US-triggered model drug release from liposomally-loaded MBs in vitro [45, 46]. In this study we have engineered thMBs with either the prodrug irinotecan or its highly toxic metabolite SN38 and investigated their biodistribution, efficacy and mechanisms of action in vivo. Using this approach, we have shown that thMBs can deliver effective doses of highly toxic drugs to tumors resulting in tumor growth inhibition without toxic side effects and may therefore provide the means to formulate existing potent but toxic drugs, novel drug combinations or previously “hard to deliver” drugs for cancer therapy.

Methods

Reagents and materials

Lipids used for MB and liposome production

Figure 1. VEGFR2 targeting of therapeutic microbubbles in human colorectal cancer. (A) Schematic depiction of a thMB (B) HCT116 CRC xenografts immunostained for CD31 and VEGFR2 with percentage of VEGFR2/CD31 double positive blood vessels related to tumor size presented (median with 95% confidence levels are denoted, **p = 0.004, Mann-Whitney U Test, two tailed). (C) The SMS (HF-US signal from VEGFR2-bound MBs minus the HF-US signal from isotype-control MBs) binned against tumor volume shows the specific binding of VEGFR2-targeted MBs in vivo (median with 95% confidence levels are denoted, not statistically significantly different). (D) Targeted microbubbles (MBs) or thMBs both with VEGFR2 targeting were flowed over SVR or PAE/KDR endothelial cells (both VEGFR2-expressing) and SW480 CRC cells (non-VEGFR2 expressing). The percentage of cells with MBs bound was calculated (see ‘Quantification of VEGFR2-targeted MB binding’ in the Methods section). Mean and SEM are plotted. Two-way repeated measured ANOVA comparing between the MB type within the same cell type shows no significant differences in binding. (E) Bioluminescent imaging of mice injected with either isotype-targeted luciferin MBs or VEGFR2-targeted luciferin MBs. The average radiance measured from the pairs of mice are shown (n = 5 pairs). Fitted with a one-phase association curve, paired t-tests, one tailed at each time point p < 0.05 for all. The curve-fitted mean and SEM are shown (R2 isotype = 0.981, R2 VEGFR2 = 0.998).
were from Avanti Polar Lipids (Alabaster, AL, USA). Texas Red® 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium salt (Texas Red® DHPE), tissue culture reagents and neotrardin were all from Invitrogen, Life Technologies (UK). Cardiolipin, sucrose, manganese sulfate, 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES), ethylenediamine tetraacetic acid (EDTA), dimethyl sulfoxide (DMSO), irinotecan hydrochloride, ethyl-10-hydroxycamptothecin (SN38), tolbutamide and calcium ionophore A23187 were all from Sigma-Aldrich (St Louis, MO, USA). 7-ethyl-10-(4-amino-1-piperidino)-carbonyloxycamptothecin (SN38G) and irinotecan-d10 hydrochloride were from Santa Cruz Biotechnology Inc. (Dallas, Texas, USA). Luciferin was purchased from Promega (Madison, WI, USA). 2,5-dioxopyrrolidin-1-yl3-oxo-1-(phenyldisulfanyl)-7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52-hexadecaoxa-4 -azapentapentacontan-55-oate (SPDP-dPEG1k-NHS ester) was purchased from Quanta Biodesign Ltd (US) and N-(3-Maleimidooxypropyl)-L-α-phosphatidyl-ethanolamine, Disteroyl (DSPE-Maleimide) was purchased from NOF Europe GmbH (Germany). ⁸⁹Zr-oxalate was purchased from Perkin Elmer (US)/BV cyclotron (Netherlands). All other chemicals were purchased from Sigma Aldrich (UK) and were used without any further purification.

Jupiter® 10 µm Proteo(C12) 90 Å, LC Column 250 × 10 mm and Jupiter® 10 µm C4 300 Å, LC Column 250 × 10 mm HPLC columns were purchased from Phenomenex LTD (UK) while a Superdex-200 10/300 HPLC column was purchased from Sigma Aldrich (UK). PD-10 size exclusion desalting columns were purchase from GE Healthcare (UK) and Amicon ultra-centrifugal filters were purchased from Sigma Aldrich (UK).

HPLC analysis was performed on a Shimadzu Prominence LC system running Laura 3 software from LabLogic and an ALC PK121R centrifuge was used as part of the ⁸⁹Zr-liposome purification/filtration process.

**Cell lines**

SW480, SW620 and HCT116 human CRC cell lines were obtained from ECACC (ecacc.org.uk). MC38 luc11A mouse syngeneic CRC cells, expressing luciferase were a kind gift from Professor R. D. Beauchamp, University of Vanderbilt, USA under a Material Transfer Agreement. SVR murine endothelial cells were purchased from ATCC. Porcine aortic endothelial cells transfected with the human VEGFR2 gene (PAE/KDR) were a kind gift from Professor L Claesson-Welsh, University of Uppsala, Sweden. Cells were maintained in RPMI with 10% (v/v) fetal calf serum (FCS, Sigma-Aldrich, St Louis, MO, USA), apart from the PAE/KDR cells which were cultured in Ham’s F12 medium supplemented with 10% FCS. The SVR cells were cultured in high-glucose DMEM with 5% FCS. All cells were maintained at 37°C in 5% CO₂. All human cell lines were authenticated in-house by tandem repeat (STR) profiling and screened negative for mycoplasma.

**Mouse models**

All experiments were performed following local ethical approval and in accordance with the UK Animals (Scientific Procedures) Act 1986. CD-1® nude mice were bred in-house under license from Charles River Laboratories (Wilmington, MA, USA) and maintained in specific-pathogen free conditions in individually ventilated cages (IVCs) with free access to water and food.

Human CRC cells were used to establish xenografts on the flank of 5-7 week old female CD1 nude mice, as described previously [47]. The numbers of mice (n) per group are detailed in each figure.

**High-frequency ultrasound imaging (HF-US)**

Tumors were imaged using a Vevo 770 high-frequency ultrasound system (Fujifilm VisualSonics Inc., Ontario, Canada) with 40 MHz (RMV-704) and 25 MHz (RMV-710B) transducers, as previously described [48]. Contrast enhanced US and quantitative molecular imaging with US destruction-replenishment and Target-Ready Micromarker (Fujifilm VisualSonics Inc., Ontario, Canada) were performed as previously described [31] using 27g tail vein catheters (SAI Infusion Technologies, IL, USA) and an infusion syringe pump (Aladdin, World Precision Instruments, UK).

**Bioluminescence imaging (BLI)**

Light microscopy was used to measure the concentration and mean diameter of MBs and DLS was used to measure the mean diameter of liposomes. Using these parameters, we calculated that 100 µL liposome-loaded MBs (Target-Ready MicroMarker), corresponding to 1 × 10⁸ microbubbles carried approximately 340 liposomes per MB. This was injected via the tail vein into MC38 luc11A tumor bearing mice. MBs were targeted using biotinylated anti-VEGFR2 antibody or isotype control antibody as described [31]. Pairs of mice with similar-sized tumors were injected via tail vein catheters to allow simultaneous imaging of targeted and untargeted liposomes. Auto exposure settings on an IVIS Spectrum (Perkin Elmer, Walton, MA, USA) were used for in vivo imaging (maximum one min exposure time) and BLI was performed every two min. Living
image software version 4.4 was used to analyze BLI signals. Auto ROIs with a threshold of 14% were used to calculate average radiance (photons/second/cm²/steradian).

**Quantification of VEGFR2-targeted MB binding**

*In vitro* binding efficiency of microfluidically-generated VEGFR2-targeted MBs and thMBs (see On-chip generation of thMBs for details) was assessed as previously described [43], using flow rates of 0.3 - 0.6 mL/min. The percentage of cells with MBs bound was calculated using the following equation:

\[
\% \text{ cells with MBs bound} = \frac{\text{Number of cells with MBs}}{\text{Total number of cells in image}} \times 100
\]

**Generation and characterization of luciferin liposomes**

Luciferin encapsulation into liposomes was performed by active acetate gradient loading through the lipid membrane [49]. The shell was composed of 56:4:0:0.1 mol% of DSPC:DSPE-PEG2000:Cholesterol:Texas Red® DHPE.

Concentrations and size distributions of liposome preparations were determined using a Q-nano instrument (Izon Science Ltd, Oxford, UK). The encapsulated concentration of luciferin was determined using an LS55 Fluorescence Spectrometer (Perkin Elmer Inc., UK) against a calibration curve of free luciferin.

**Generation and characterization of irinotecan liposomes**

The lipid shell was composed of 63:32:5:0.1 mol% DSPC:Cholesterol:DSPE-Biotin-PEG2000:Texas Red® DHPE. Irinotecan encapsulation was performed by the manganese sulfate pH gradient method, as previously described [50]. Liposomes were sized and their concentration determined by Q-nano (Izon Science, Oxford, UK). The stability of liposomes was examined by measuring the irinotecan concentration, size distribution and liposome concentration for a sample that was stored at 4 °C over a period of 8 weeks. Encapsulated irinotecan was quantified by HPLC (see below for HPLC methods).

**Generation and characterization of SN38 liposomes**

The lipid shell of SN38 liposomes was comprised of 57:39:4:0.1 mol% of DSPC:Cholesterol:DSPE-Biotin-PEG2000:Texas Red® DHPE. 11% by weight of cardiolipin was also added to the shell. SN38 was dissolved in 0.1 M ammonium hydroxide to 2 mg/mL and the encapsulation procedure was carried out as previously described [51]. Liposomes were frozen in aliquots in liquid nitrogen, dehydrated by freeze drying then stored at 4 °C until required. Samples were rehydrated prior to use with 10 mM acetate buffer, pH 2 and filtered through a 200 nm filter. The encapsulated concentration of SN38 was measured by tandem mass spectrometry (see below for details). Liposomes were sized and their concentration was measured by DLS (Malvern) and NanoSight (Malvern). A Zetasizer (Malvern Instruments Ltd, UK) was used to measure the zeta potential, by passing a voltage through the sample and mixed measurement model phase analysis (M3-PALS) technology determined the mean reading in mV. The zeta potential was determined as -50.2 ± 7.7 mV, suggesting these liposomes would have long term stability with minimal aggregation.

**Synthesis of Df-PEG1k-SPDP**

The synthesis of Df-PEG1k-SPDP was carried out according to the method described [52]. First deferoxamine mesylate (39 mg, 60 µmol) was dissolved in DMSO (1 mL) and SPDP-PEG1k-NHS (65 mg, 60 µmol, in DMSO (1 mL)) and diisopropylethylamine (7.8 mg, 60 µmol, 10.5 µL) were added. The reaction solution was stirred at room temperature for 4 h and monitored by HPLC (Jupiter® 10 µm Proteo (C12) 90 Å, Column, 250 x 10 mm). Upon completion the reaction mixture was poured into deionized water (0.5 mL) and the product was isolated by HPLC with an eluent system of solvent A = water (0.05 % TFA) and solvent B = acetonitrile (0.05 % TFA) running at a gradient of 10 to 60 % solvent B over 30 min at a flow rate of 3 mL/min with a UV detector wavelength of 220 and 280 nm.

**Synthesis of Df-PEG1k-DSPE**

The synthesis of Df-PEG1k-DSPE was carried out according to the method described [52]. DSPE-maleimide (15 mg, 16 µmol) was suspended in distilled water (0.5 mL) and sonicated at 50 ºC until the solution became clear before being cooled to room temperature. Df-PEG1k-SPDP (46 mg, 30 µmol) from the previous step was then dissolved in distilled water (1 mL) and the pH was adjusted to 7.3 with NaOH (1 M). TCEP (0.1 M, pH 7, 1 mL) was added to the Df-PEG1k-SPDP solution and the mixture was incubated at room temperature for 10 min. Both solutions, Df-PEG1k-SPDP and DSPE-maleimide were combined and the pH was re-adjusted to 7.0-7.3 before the reaction mixture was incubated at room temperature for 4 h. After incubation the pH of the reaction mixture was adjusted to pH 2 – 3 and Df-PEG1k-DSPE was isolated by HPLC (Jupiter® 10 µm C4 300 Å, column 250 x 10 mm) with an eluent
system of solvent A = water (0.05% TFA) and solvent B = acetonitrile (0.05% TFA) running at a gradient of 50 to 90 % solvent B over 40 min at a flow rate of 3 mL/min with a UV wavelength of 220 and 280 nm.

**Incorporation of Df-PEG1k-DSPE onto liposomes**

The lipid shell of SN38 liposomes was comprised of 57:39:4 mol% of DSPC:Cholesterol:DSPE-PEG2000. 11% by weight of cardiolipin was also added to the shell along with 1 mol% of Df-PEG1k-DSPE.

**Zirconium-89 radiolabeling of Df modified liposomes**

First, freeze dried Df-modified liposomes were reconstituted in 10 mM sodium acetate buffer, pH 2 (250 µL) before being passed through a 200 nm syringe filter. Next 89Zr-oxalate (230 µL, approx. 220 MBq) was neutralized by the addition of Na2CO3 (2 M, 105 µL) and the mixture was incubated at room temperature for 5 min. Following the incubation HEPES buffer (0.5 M, pH 7, 1 mL) and the filtered Df-modified liposomes (200 µL) were added. The radiolabelling solution was incubated at room temperature for 60 min followed by the addition of EDTA (0.1 M, 100 µL). Next the reaction mixture was applied to a PD-10 size exclusion purification column (250 µL) before being passed through a 200 nm syringe filter. Next 89Zr-oxalate (230 µL, approx. 220 MBq) was neutralized by the addition of Na2CO3 (2 M, 105 µL) and the mixture was incubated at room temperature for 5 min. Following the incubation HEPES buffer (0.5 M, pH 7, 1 mL) and the filtered Df-modified liposomes (200 µL) were added. The radiolabelling solution was incubated at room temperature for 60 min followed by the addition of EDTA (0.1 M, 100 µL). Next the reaction mixture was applied to a PD-10 size exclusion purification column and 89Zr-liposomes were eluted in phosphate buffered saline (PBS). Finally the 89Zr-liposome mixture was filtered on a 100 kDa MWCO centrifuge filter at 12000 rpm for 20 min to give 89Zr-liposomes in approximately 0.4 mL of PBS. For quality control analysis 50 µL of the purified 89Zr-liposomes were injected onto a Superdex 200 size exclusion column eluted with PBS at 0.8 mL/min. Df modified liposomes were successfully radiolabelled with 89Zr to give 41.2 ± 10.8 MBq (n = 3) of 89Zr-liposomes in a non-decay corrected radiochemical yield of 18.7% ± 4.9 (n = 3). The radiochemical purity of 89Zr-liposomes was 87.1% ± 0.8 (n = 3) as determined by size exclusion HPLC.

**On-chip generation of therapeutic MBs**

The generation of thMBs was carried out in a microfluidic device as previously described [43, 44]. Briefly, 8 µL 2.5 mg/mL neutravidin was added per 100 µL of liposomes and incubated for 20 min. This was then incubated with 2 mg/mL DPPC, DSPE-biotin PEG1k and 10 µL/mL C6F14 liquid was added (Sigma-Aldrich, St Louis, MO, USA) to improve MB stability [44] before generating liposome-loaded microbubbles using a patented microfluidic chip-based system. The microbubbles were counted and sized by taking light microscopy images of the resulting microbubbles and 0.1 µg of biotinylated anti-mouse VEGFR2 antibody was added per 10^7 microbubbles and incubated for 20 min before injection.

**In vivo delivery and ultrasound triggering**

CD1 nude female mice aged 5-7 weeks were inoculated with 10^7 SW480 CRC cells on the right hind flank. After 7 days, mice were randomly assigned to a treatment group. ThMBs or free drug were administered via tail vein injection. Animals in the thMBs + trigger (T) group received an US pulse at the tumor site 4 min post MB injection using a custom-built single element ultrasound system (UARP) [45]. A 2.2 MHz, 10 µs ‘tone burst’ US pulse was generated by an unfocused transducer (V323, Olympus NDT, UK), with a peak negative pressure of 260 kPa that had a 1 kHz pulse repetition frequency (PRF). The total sonication time was 5 s. The US-trigger had an MI of 0.21 by Church approximation [53] and a thermal index in soft tissue of 0.09, both of which are considered safe for all diagnostic US applications.

**High-performance liquid chromatography (HPLC)**

For quantification of irinotecan loading into liposomes and final MB preparations, HPLC was used. Irinotecan was dissolved in DMSO to 2 mg/mL and a 6-point standard curve diluted 1:1 from 1 mg/mL was prepared in methanol. thMB samples were diluted 1:1 in methanol, vortex mixed and centrifuged at 10,000 g for 4 min at 4°C to remove lipids. Irinotecan liposomes alone were diluted 1:10 in methanol then treated as the thMB sample. Samples were analyzed using a Waters Alliance 2695 HPLC (Waters Corporation, Milford, MA, USA) linked to a Waters 2996 Photodiode Array Detector detector. 10 µL of sample was eluted using a stepwise gradient at a flow rate of 1 mL/min on a Hichrom RPB column (3.5 µm, 25 cm x 2.1 mm) (Hichrom Limited, UK). Mobile phase A consisted of 90% (v/v) dH2O, 10% (v/v) methanol and 0.1% (v/v) formic acid, and mobile phase B consisted of 90% (v/v) methanol, 10% (v/v) dH2O and 0.1% (v/v) formic acid. The initial gradient of 90% A: 10% B was gradually increased to 90% B over 7 min, held for 2 min and returned to the initial gradient over 1 minute and held at this to give a total run time of 15 min. The area under the curve at 373 nm was calculated using Empower Pro software (Waters) and comparison to the standard curve was used to determine concentration of irinotecan in liposomes and in each MB preparation. These mobile phases allowed direct conversion to mass spectrometry.

**Tandem mass spectrometry (LC-MS/MS)**

Irinotecan, SN38 and SN38G were dissolved in
DMSO as fresh 1 mg/mL stock solutions and a 6-point standard curve diluted 1:1 from 1 µg/mL was prepared in methanol. Mouse tumors and tissues were weighed and homogenized in methanol on ice using an Ultra Turrex® blender (Janke and Kunkel, IKA). A clear supernatant was obtained by centrifugation at 10,000 g for 4 min at 4 °C and analyzed by LC-MS/MS. An internal standard (irinotecan-d10 hydrochloride) was also prepared in methanol and spiked into each sample at a concentration of 1 µg/mL. Multiple reaction monitoring (MRM) mass spectrometry was performed on a Waters Quattro Ultima triple quadrupole mass spectrometer with an electrospray ionization source operating in positive ionization mode (LC-MS/MS). Compounds were eluted using a stepwise gradient at a flow rate of 0.3 mL/min where mobile phase A and B were as described for HPLC above, on an Acuity UPLC BEH C18 column (1.7 µm, 2.1 × 100 mm) (Waters Corporation, Milford, MA, USA). The column was heated to 40 °C. The initial gradient of 80% A: 20% B was gradually increased over 15 min to 80% B, then increased over 1 min to 100% B and held for 4 min then returned to the initial gradient over 1 min and held for 14 min, with a total run time of 35 min. Instrument settings: Capillary voltage, 3.50 kV; Cone energy, 12 V; Source temperature, 120 °C; Desolvation temperature, 250 °C; Gas flow desolvation, 650 L/h; Cone, 60 L/h. MRM settings were optimized using pure irinotecan and SN38 as described previously [54]. The peak area calculated using Masslynx software (Waters Corporation) and comparison to the standard curve was used to determine drug concentrations.

For quantification of SN38 loading into liposomes and final MB preparations, LC-MS/MS was used. Samples were prepared as previously stated for irinotecan liposomes and MBs and analyzed using the LC-MS/MS conditions stated below for SN38 tissue samples.

Tissues were weighed and homogenized in methanol spiked with 10 ng/mL internal standard tolbutamide (Sigma-Aldrich) using a Bead Ruptor 24 Bead Mill Homogenizer (OMNI International Inc.) with 2.8 mm zirconium ceramic oxide beads. A clear supernatant was obtained by centrifugation at 10,000 g for 4 min at 4 °C. Standard curves for SN38 and SN38G were prepared as described previously with tolbutamide spiked methanol, and analyzed by LC-MS/MS using mobile phases and column as described above. The initial gradient of 80% A: 20% B was gradually increased over 16 min to 100% B then returned to the initial gradient over the following 4 min and held, for a total run time of 25 min. Instrument and MRM settings were as described above.

**Positron Emission Tomographic Imaging of radiolabelled liposomes and therapeutic MBs**

SW480 tumor bearing CD1 nude female mice were injected intravenously with 100 µL of either $^{89}$Zr-labelled SN38 liposomes ($n = 15$ mice) or thMBs carrying the $^{89}$Zr- labelled SN38 liposomes ($n = 15$ mice). Both were conjugated to anti-VEGFR2 antibodies. The injections contained the same number of radiolabeled liposomes per MB (~340) and at 2 MBq per injection. The therapeutic MB group was also subject to an US-trigger as described in ‘In vivo delivery and ultrasound triggering’. Imaging was performed using the Inveon Multimodality TM PET scanner (Siemens Medical Solutions) for 20 min in a supine position after 1, 24 and 72 h post-injection. Five mice per time point were imaged and had their tissue collected after imaging. Data were acquired using Inveon Acquisition Workplace (IAW) software (Siemens) version 2.1 and analyzed using Inveon Reconstruction Workplace (IRW) software (Siemens) version 2.2.0. Images were reconstructed using the order subset expectation maximization (OSEM)/maximum a posteriori (MAP) algorithm.

Tissues were weighed and were counted in a gamma counter (Perkin Elmer, 1480, Wizard 3) for 20 s per sample. The gamma counter provides a “counts per minute” parameter. These data were imported into an Excel spreadsheet where the counts per minute were converted into activity by conversion into disintegrations per minute; by multiplying the efficiency of the gamma counter for $^{89}$Zr. Activity was decay corrected to the time of injection and converted into a concentration using the ex vivo tissue weight (in kilobecquerel per gram). All mice in which $^{89}$Zr radioactivity in the tail exceeded 10% of the injected dose were excluded from analysis.

**Tissue processing, immunohistochemistry and pharmacodynamic analysis**

Paraformaldehyde-fixed tumors and tissues were processed using a tissue processor and embedded in paraffin. 4 µm central sections were cut and one section from each sample was stained with hematoxylin and eosin (H and E). Slides were scanned using an Aperio digital slide scanner (AT2, Leica Biosystems) at ×20 magnification with ImageScope software (Leica Biosystems) at 0.5 µm/pixel. JPEG compression quality 70 was used to quantity digital slide images for mitotic bodies, which were counted by a reviewer blinded to the experimental groups. ImageScope was then used to manually annotate the boundary of the tumor area on the digital slide, in order to calculate the number of mitoses/mm².
IHC detection of CD31-positive blood vessels was performed as previously described [55] except heat-mediated antigen retrieval in citrate buffer, pH 6.0 was used. Slides were digitally scanned at ×20 magnification to facilitate image analysis and scoring. For quantification of CD31 positive blood vessels, ten 0.25 mm² boxes were placed randomly across the tumor section using RandomSpot software version 6.02 [56] and the number of CD31-positive vessels counted as described [57].

VEGFR2-positive blood vessels were identified and quantified in tissues using immunostaining with an anti-mouse VEGFR2 antibody (55B11, Cell Signaling Technologies). Sections were deparaffinised before heat-mediated antigen retrieval in Tris/EDTA/Tween-20 (10 mM/1 mM/0.05%) buffer pH 9.0. Endogenous peroxidases and casein were also blocked, and then sections were incubated with rabbit anti-mouse antibody at 1:100 dilution [58]. pH2AX was used as a surrogate marker for irinotecan efficacy, as topoisomerase 1 inhibition causes single-strand DNA breaks, which are then converted to double-strand breaks during S phase. The entire tumor area was digitally scanned at ×20 magnification. VEGFR2 positive vessels in each tissue section were counted by a blinded observer.

Cleaved Caspase 3 staining of the tumors as a biomarker of apoptosis [47] and phosphorylated histone H2AX (pH2AX) staining were carried out manually as described, except the latter antibody was applied at a 1:400 dilution [58]. pH2AX was used as a surrogate marker for irinotecan efficacy, as topoisomerase 1 inhibition causes single-strand DNA breaks during S phase. The entire tumor area was digitally scanned at ×20 magnification. An in-house developed algorithm was used to extract each region and block process the tissue at full resolution, using color deconvolution to separate staining channels into hematoxylin and DAB images, for analysis independently [59]. The intensity of DAB staining was co-localized with a basic binary mask of foreground tissue (generated by thresholding of hue, saturation and intensity channels), in order to obtain the total percentage of positive pixels within the tumor area. The resulting percentage positive pixels were divided by the tumor area, as described previously.

Transmission electron microscopy (TEM)

Liposomes and thMB morphology was evaluated using negative staining technique with transmission electron microscope (TEM) JEM1400, 120KV instrument (JEOL, USA). For sample preparation, 8 µL of diluted liposome sample (10¹¹/mL) or thMB sample (10⁹/mL) was placed on a coated carbon grid. The solution was left on the grid for 30 s, and the excess liquid was removed out with filter paper. Another 8 µL of 1% uranyl acetate was subsequently added to stain the sample, incubated for 15 s, then the excess liquid was removed with filter paper, and was finally dried at room temperature.

Quantitating perivascular inflammation

For perivascular inflammation scoring in the livers of treated animals, H and E stained liver sections were digitally scanned at ×20 magnification. The area of inflammation (µm²) per tissue section was determined by a blinded observer using ImageScope. Percentage inflammation was determined by dividing area of inflammation (µm²) by area of liver section (µm²) × 100.

Alanine aminotransferase (ALT) liver enzyme analysis

Plasma samples were analyzed at The Mary Lyon Centre, Pathology, Medical Research Council, Harwell, Oxfordshire, UK. A Beckman Coulter AU680 clinical chemistry analyzer (Beckman Coulter, Inc., CA, USA) was used to determine ALT concentrations.

Statistical analyses

All statistical analyses were performed using GraphPad Prism version 8 software. Statistical tests used for each experiment are described in figure legends.

Results

VEGFR2 targeting of therapeutic microbubbles in human colorectal cancer

We first assessed VEGFR2 as a candidate biomarker for tumor blood vessel-specific binding of thMBs in human CRC xenografts. This showed approximately 2.5× more VEGFR2 positive blood vessels in smaller tumors (up to 200 mm³) than larger tumors (up to 750 mm³) ex vivo (Figure 1B and Figure S1A-B). To relate the immunohistochemical detection of VEGFR2 positive blood vessels with functional VEGFR2 targeting in vivo, we used contrast enhanced US with quantitative analysis of VEGFR2 MB binding. Subtracted molecular signals (SMS) equating to the signal from VEGFR2-targeted MBs were higher (but not significantly different) in smaller than larger tumors (11 ± 2.4 versus 6 ± 2.5, respectively, Figure 1C and Figure S1 C-D) suggesting that in this model, there was sufficient VEGFR2 across all tumor sizes for it to be actively targeted by thMBs.

To assess the potential for off-target binding, we examined VEGFR2 immunoreactivity in mouse tissues and determined SMS in vivo. VEGFR2 was
detected in the fenestrated endothelial cells of the liver sinusoids but not in the endothelial cells of the hepatic venules, with weaker staining in kidney cortex and red pulp of the spleen. These areas also demonstrated SMS signals in vivo from targeted MB binding (Figure S1E-F). Although VEGFR2 is not entirely tumor specific, drug release from thMBs bound to VEGFR2 in non-tumor vessels would potentially be avoided as the US-trigger is localized to the tumor site alone.

thMBs were generated by attaching liposomes to the MB shell (see Figure S1G and [43]) and VEGFR2 antibody was bound as described in the methods. Under flow conditions in vitro, thMBs showed specific binding to VEGFR2 positive cells (Figure 1D). Both mouse (SVR) and human (PAE/KDR) VEGFR2 positive endothelial cells bound targeted MBs and thMBs at significantly higher levels ($p < 0.0001$, two-way repeated measure ANOVA) than SW480 CRC cancer cells which showed minimal binding of MBs. Furthermore, there were no significant differences in binding by VEGFR2-targeted MBs alone or thMBs on endothelial cells, confirming that addition of the liposomal payload did not affect targeting efficiency in vitro.

We next assessed the ability of thMBs to target a payload in vivo, using luciferin as a model liposomal drug for delivery to luciferase-expressing mouse colorectal MC38 xenografts and quantified tumor bioluminescence (BLI) over time [49]. Tumor BLI in mice receiving intravenous VEGFR2-targeted luciferin MBs was significantly higher than in those targeted with an isotype-control antibody (Figure 1E and Figure S1G). Linear regression analysis of the curves showed no difference between the slopes but significant differences in the intercepts ($p = 0.007$) indicating that the rate of release of luciferin from MBs was constant but that there was greater initial delivery of luciferin to the tumor with VEGFR2 targeting and ensuing uptake throughout the tumor due to its highly water soluble nature and the inherent leakiness of the luciferin liposomes. We therefore used VEGFR2-targeting in subsequent experiments to target drug loaded thMBs to the tumor vasculature and investigate US-mediated thMB delivery of cytotoxic drugs in vivo.

**Therapeutic microbubbles enhance tumor responses to irinotecan**

To determine if thMBs could enhance tumor-specific delivery of a chemotoxic payload in vivo, we produced thMBs containing irinotecan (Figure S2 and Tables S1A and S1B). Irinotecan is a member of the camptothecin class of drugs with proven survival benefits as a standard first-line therapy containing fluorouracil-leucovorin-irinotecan (FOLFIRI) with or without bevacizumab in CRC. However, severe adverse effects (diarrhea and neutropenia) often lead to altered dosing schedules or preclude its use [60].

We compared tumor drug concentrations, drug metabolism and tumor responses in vivo with and without an US-trigger using a bolus of $10^8$ thMBs (intravenous injection volume of the thMBs ranged from 150-200 µL in order to maintain this) consistent with contrast-enhanced US imaging protocols in mice [61, 62]. This equated to approximately 2 mg/kg irinotecan per treatment (Tx), 25× lower than the standard therapeutic dose for mice [63].

The treatment groups and protocols used are shown in Figure 2A and B, respectively. The customised US-trigger (+T) directed at tumors was a high amplitude, low frequency tone burst with a duration of only 5 s designed to induce MB bursting or cavitation within the tumor [45]. This had a Mechanical Index (MI) of 0.21 using the Church approximation [53] and a thermal index in soft tissue of 0.09, both of which are considered safe for all diagnostic US applications. In pilot studies, we showed that this US destruction pulse had no significant effect on the growth of human CRC xenografts (HF-US ratio to day 0 for vehicle was 5.47 ± 1.06 and vehicle +T was 5.76 ± 0.98 (mean, ± SEM; $n = 4$ and 6 per group respectively).

As shown in Figure 2C, irinotecan thMBs +T significantly inhibited the tumor growth rate compared with the vehicle control across all imaging time points and with the equivalent dose of free irinotecan on day 18. Tumor mass was also significantly reduced compared to vehicle and tumor doubling time significantly increased (Figure 2D-E). The % tumor growth inhibition (%TGI) compared to vehicle (% TGI = 1 - (treated final - treated day 0)/(control final - control day 0) [64]) was 38% for free irinotecan and 50% for thMBs + T. In addition, if the free irinotecan is used as the control in the equation, the thMBs +T show a 19% TGI compared to free irinotecan. There was no significant reduction in tumor growth in the thMBs -T group (% TGI -4%) demonstrating that an US-trigger was essential for effective drug release, penetration and/or retention in tumors. Irinotecan-induced biomarker levels changed in all three treatment groups (Figure S3A-D) but were significantly enhanced with thMBs + T (tumors showed fewer mitotic cells, increased double strand breaks and apoptotic cells but no change in blood vessel density). Therefore, US-driven thMB delivery apparently increased the potency of irinotecan at these low doses.

To determine if the enhanced tumor responses with thMBs +T were due to altered pharmacokinetics
(PK) of drug delivered in this way, we used LC-MS/MS to quantify levels of irinotecan and its active and inactive metabolites (SN38 and SN38 glucuronide [SN38G] respectively) in tumors from all treatment groups, collected 72 h after the final treatment. Irinotecan and SN38 were detected only in tumors from the thMBs +T group (Figure 2F) with median (± range) levels of 47 (± 102) ng/g and 2.2 (± 60.4) ng/g tissue, respectively. Both values lie within the effective therapeutic doses in vitro (data not shown). No SN38G was detected. Irinotecan and SN38 were below the limit of detection (LOD) in all tumors from the free drug and thMBs -T groups (Figure 2F) showing that the US-trigger was required for the enhanced tumor drug accumulation/retention. The extraction efficiencies, stability of compounds and LOD are shown in Tables S2A-C and Figure S4.

Irinotecan and SN38 were also detected in other tissues of the thMBs +T group (Figure 2G). Irinotecan was present in kidney and spleen, with traces of SN38 in a single kidney and single spleen. In the thMBs -T group, irinotecan and SN38 were only detected in colon where 4/7 (57%) had detectable irinotecan and 4/8 mice (50%) had detectable SN38 levels. 1/7 (14%) or 2/7 mice (29%) also had detectable levels of irinotecan or SN38 respectively, in colon in the free drug group (Figure S5). This shows that both the free drug and thMBs -T groups had been exposed to irinotecan but that the drug had been metabolised and eliminated and was below the LOD in tumor and liver, indicating an altered PK response with thMBs +T delivery.

We next compared the relative amounts of irinotecan and SN38 in tissues to assess irinotecan metabolism as a surrogate marker of drug release (LC-MS/MS cannot differentiate between liposomally encapsulated or unencapsulated ‘free’ drugs). Highest relative amounts of SN38 were found in tumor and colon suggesting greater conversion of irinotecan to SN38 in these tissues (Figure 2H). In contrast, there were relatively low amounts of SN38 in the liver suggesting limited conversion prior to elimination via hepatobiliary clearance. Persistent liposomal encapsulation of irinotecan and sequestration in cells of the mononuclear phagocytic system (MPS) through which NPs and liposomes are cleared [65-67], may explain this. In rodents, up to 50% of irinotecan is converted to SN38, whereas humans convert less than 8% [68, 69]. This suggests that thMB +T targeted delivery of SN38 itself might be more clinically effective.

There was no significant correlation between absolute amounts of irinotecan and SN38 in tumors (Spearman’s correlation $r = 0.48, p = 0.3$) or livers (Spearman’s correlation $r = 0.59, p = 0.13$), suggesting non-linear conversion kinetics in both tissues. This may reflect saturable carboxylesterase-converting enzymes or inaccessibility of drug for metabolism due to persistent encapsulation in intact liposomes. By contrast, ratios of irinotecan:SN38 in colon from all groups were close to 1 suggesting a linear conversion rate as indicated by a significant Spearman’s correlation ($r = 0.835, p = 0.0007$) between individual levels of irinotecan and SN38. This suggests direct conversion of irinotecan to SN38 or deglucuronidation of SN38G to SN38 in the gut microenvironment consistent with bacterial metabolism of irinotecan [70].

**Free irinotecan shows rapid metabolism and excretion in vivo**

We next performed a small study to examine how tumor PK and biodistribution of irinotecan delivered via targeted US-triggered delivery compared with free drug at high dose (50 mg/kg, relevant to routine clinical doses) or at low dose (2 mg/kg, relevant to the dose delivered by thMBs) (Figure 3). At 1 and 24 h post-injection of free drug, the levels of irinotecan, SN38 and SN38G were measureable indicating drug delivery and metabolism through to the glucuronidated form was possible in all tissues. The 50 mg/kg dose gave high circulating levels in serum at 1 hour with higher levels in liver, kidney and spleen and the lowest level in tumor. Low dose drug followed a similar pattern with tumor irinotecan levels at 1 hour equivalent to those measured at 72 h post thMB +T administration of the same drug dose. At 72 h post injection of free drug there was no detectable drug in any tissues except for irinotecan in a single kidney and spleen, showing that the altered PK observed with thMBs was not due to the use of a lower dose alone.

**SN38 delivery with US-triggered therapeutic microbubbles significantly inhibits tumor growth**

To determine if the benefits of thMB delivery in terms of improved PK and tumor responses could be extended to a more cytotoxic molecule, we investigated delivery of SN38 directly as its efficacy at very low doses would be appropriate to the thMB delivery platform. Free SN38 is poorly water soluble with a high partition coefficient (logP 2.65) and cannot be delivered in free drug form without an accompanying high concentration of solvent such as DMSO, thus encapsulation has been the subject of intense research [71-73] and at least one formulation has reached clinical trials [74]. SN38 was encapsulated in liposomes and used to formulate SN38 thMBs (Figure S6 and Tables S3A-B). The experimental
groups and dosing schedule used for in vivo evaluation of SN38 thMBs + T are shown in Figure 4A and B respectively and were used to deliver 0.4 mg/kg SN38 per Tx.

Figure 2. Therapeutic microbubbles enhance tumor responses to irinotecan. (A) Treatment groups used (n = number of mice per group). The abbreviated nomenclature used in subsequent figures is shown. (B) Schematic of the experimental protocol is shown with timing of each treatment (Tx) and 3D high frequency ultrasound (HF-US) imaging. The mean (± SEM) starting tumor volumes for each group were 65 (± 7.9) mm³ for vehicle, 76 (± 12.5) mm³ for free, 72 (± 11.5) mm³ for the thMBs - T (no US-trigger) and 85 (± 14.3) mm³ for the thMBs + T group which are not statistically significantly different at this time point. (C) Effect of thMBs on tumor volume (mean ± SEM) ratio to day 0. Unpaired Mann-Whitney test *1 p = 0.0152 (vehicle vs thMBs + T), *2 p = 0.0311 (vehicle vs free), **3 p = 0.0025 (vehicle vs thMBs + T), *4 p = 0.0229 (vehicle vs free), *5 p = 0.0152 (free vs thMBs + T), *6 p = 0.0001 (vehicle vs thMBs + T). (D) Final tumor mass, unpaired Mann-Whitney test p = 0.036. (E) Tumor doubling time, unpaired Mann-Whitney test p = 0.040. (F) Irinotecan and SN38 were only detected by LC-MS/MS analysis in tumors from the thMBs + T group at 72 h post final treatment. LOD indicates the drug was below the limit of detection. (G) Irinotecan and SN38 in tissues from the thMB + T group at 72 h post final treatment (median values are indicated). (H) Relative amounts of irinotecan and SN38 showing tumor and colon with highest relative levels of conversion of irinotecan to SN38.
There was significant inhibition of tumor growth at days 7 and 14 post treatment (Figure 4C). Reduced tumor masses and complete regression of one tumor in the thMB +T group were observed (Figure 4D). Tumor doubling times were increased or abolished (tumors regressed in volume) in the thMB +T group. Apoptosis and double-strand DNA breaks were also significantly increased as revealed by caspase 3 (Figure 4F) and pH2AX staining (Figure 4G). The extremely low doses of drug (0.4 mg/kg) delivered by thMBs +T gave 93% TGI. This compared favorably with liposomal SN38 at 8 mg/kg previously shown to give 81-91% tumor growth inhibition in mouse CRC models [75-77].
Figure 4. SN38 delivery with US-triggered therapeutic microbubbles significantly inhibits tumor growth. (A) Abbreviated nomenclature and treatment groups subsequently denoted in brackets used are shown (n = number of mice per group). (B) A schematic of the experimental plan is shown with each treatment (Tx, 0.4 mg/kg SN38) and 3D high frequency ultrasound (HF-US) imaging denoted. The mean (± SEM) starting tumor volumes for each group were 100 (± 13.2) mm³ for vehicle +T and 106 (± 16.6) mm³ for the thMBs +T group which were not statistically significantly different at this time point. (C) The mean (± SEM) ratio to day 0 tumor volume measured by 3D HF-US is shown. Unpaired Mann-Whitney test *1 p = 0.048, *2 p = 0.0159. (D - E) Final day tumor mass was measured and tumor doubling time calculated (negative tumor doubling times indicate tumor regression). The median value for each group is denoted by a line (neither statistically significantly different). (F - G) Apoptosis and double-strand breaks, the median (+ range) value for each group are denoted. Apoptosis p = 0.0159 and double-strand breaks p = 0.0317, unpaired Mann-Whitney test. (H) Biodistribution of SN38 within all tissues 72 h post final treatment. No SN38G was detected.
SN38 was detected in all tumors where sufficient tissue remained at endpoint (4/5) for LC-MS/MS analysis. SN38 was also present at increased levels in other tissues but not in plasma (Figure 4H). However, SN38G was not detected suggesting that SN38 remained encapsulated and/or released over time and was below the LOD. This is consistent with irinotecan thMBs +T. ThMB +T delivery increased tumor drug uptake/retention and/or exposure resulting in significant inhibition of tumor growth at a dose 20× less than that given in liposomally encapsulated SN38 studies [75-77].

Irinotecan treatment is often restricted by its dose-limiting side effects. Life-threatening diarrhea, neutropenia and myelosuppression are induced by the active SN38 [60]. None of the mice from the SN38 thMB +T group (or previous irinotecan thMB groups) exhibited signs of such toxicity (Figure S7A-E) suggesting that retention of encapsulated drug in tissues following SN38 thMB +T delivery produced no detectable effects.

**89Zr-labelled SN38 thMBs +T show increased tumor drug accumulation and altered tissue pharmacokinetics compared to VEGFR2-targeted 89Zr-labelled SN38 liposomes alone**

One strategy to improve liposomal delivery to solid tumors to overcome poor penetration, poor drug potency and inefficient drug release has been to functionalize the surface of the liposome with targeting ligands including peptides, antibodies or aptamers and several actively targeted formulations are in clinical trials [78].

To directly compare targeted delivery by thMBs with a clinically relevant nanoformulation, we carried out 89Zr-radiolabelled distribution studies with longitudinal PET imaging in mice. Mice bearing human CRC xenografts were used to examine biodistribution and quantitate uptake of VEGFR2-targeted 89Zr-SN38 liposomes alone compared with 89Zr-SN38 thMBs +T (depicted in Figure 5A). Radiolabelling of pre-formed liposomes incorporating a deferoxamine chelator was necessary as SN38 itself was not amenable to direct labelling with 89Zr due to its relatively small size. Treatment groups and protocols used are shown in Figure 5B and C respectively.

PET images at 1, 24 and 72 h post intravenous injection with 89Zr-SN38 thMBs +T (Figure 5D) showed a similar distribution pattern to VEGFR2-targeted 89Zr-SN38 liposomes alone, with the majority of the signal detected in liver. Signal was also evident in spleen and lymph nodes suggesting clearance predominantly through the MPS system, as previously described for liposomes [65-67] and VEGFR2-targeted MBs [79].

Ex vivo radiocounting was used to quantitate the percentage injected dose in different tissues (%ID/g tissue) over time. This showed significantly increased (approximately twice as much) 89Zr in tumors at all time points in the 89Zr-SN38 thMBs +T group compared with VEGFR2-targeted 89Zr-SN38 liposomes alone (Figure 5E). There was also significantly increased signal from thMBs in blood at one hour post injection compared to free liposomes which declined to similar levels by 24 h (Figure 5F) suggesting enhanced retention and circulation of thMBs in the vascular space compared with targeted liposomes alone. By 72 h post-injection, there was a significant difference in %ID/g tissue in liver and spleen, with relatively less in liver and more in spleen in the 89Zr-SN38 thMBs +T group. There was also a difference in the ratio of %ID/g in liver and spleen compared to tumor (Figure S8B-C) with a significant 3-fold decrease in liver to tumor ratio %ID at all time points.

**Discussion**

We show here how thMBs can enhance the efficacy of cytotoxic drugs in vivo by increasing the concentration of encapsulated drug in the circulation, increasing tumor drug accumulation/retention and limiting bioavailability and toxicity in normal tissues. Sensitive LC-MS/MS quantification of drugs and their metabolites showed that thMBs limited exposure in normal tissues by persistent encapsulation of the drug, consistent with uptake by the MPS in tissues not exposed to US. The extended therapeutic range appears to be due to multiple factors that contribute to altered drug distribution, metabolism and route of elimination, thereby achieving significant therapeutic responses with very low doses of cytotoxic drugs. The different payloads used in this study demonstrate the flexibility and ease of use of a microfluidic production platform for generating thMBs in a simple ‘one-pot’ approach, with potential for scale-up and a route to clinical grade production for human trials.

These data show that thMB efficacy in vivo can be attributed to the combination of several different factors. VEGFR2 provided a tumor vasculature target for the accumulation, binding and/or anchoring of thMBs within the tumor microenvironment. Like others [31, 80], we found this interaction to be specific compared to control antibodies or non-VEGFR2 expressing cells and correlated with expression of VEGFR2 in tumors. Using VEGFR2 targeting to tumor endothelium, thMBs potentially increase the number of MBs and liposomes tethered in close proximity to the vessel walls. It is this proximity which presumably
aids intra- and/or intercellular drug delivery as VEGFR2-targeted MB delivery of luciferin showed higher initial uptake of luciferin in tumors in the absence of an US-trigger.

Figure 5. Improved tumor accumulation of \(^{89}\text{Zr}\)-labelled SN38 thMBs +T compared with VEGFR2-targeted \(^{89}\text{Zr}\)-labelled SN38 liposomes alone. (A) Schematic depicting the strategy used for radiolabeling of SN38 liposomes and SN38 thMBs. DSPE was radiolabeled with \(^{89}\text{Zr}\) and incorporated into the lipid shell of liposomes encapsulating SN38 and used to generate therapeutic MBs. (B) Schematic of the experimental groups used to compare VEGFR2-targeted liposomally encapsulated SN38 (LE-SN38) with SN38 thMB +T (\(n\) = number of mice per group). (C) Schematic of the experimental protocol used (\(n\) = 5 animals per time point). The mean (± S.D.) starting tumor volume measured by mechanical calipers was 340 mm\(^3\) ± 134 mm\(^3\). (D) PET image from the thMB +T group at each imaging time point. Signal in the liver, spleen and bladder are arrowed, tumor is circled. (E) The percentage injected dose per gram of tissue (%ID/g tissue) in tumor (F) blood (G) liver and (H) spleen were calculated with mean and SEM shown. Unpaired T-test tumor, \(* * * * p = 0.0006\) at 1 h, \(p = 0.0432\) at 24 h, \(p = 0.026\) at 72 h. Blood \(* * * * * p < 0.0001\) at 1 h, liver \(p = 0.0494\) at 72 h, spleen \(p = 0.0326\) at 72 h.
The US-trigger was shown to be essential for the selective effects of VEGFR2 targeted thMB delivery of stably encapsulated irinotecan as without the trigger, thMBs failed to extend intra-tumoral drug delivery or demonstrate enhanced tumor responses. The effects of the 5 s US-trigger were long-lasting and widespread as shown by the extended drug retention in tumors and also in tissues at 72 h. Zhang et al. [25] also showed that an US-trigger enhanced tumor responses more than endothelial targeting (via RGD) in breast cancer xenografts, using liposome-loaded MBs, although they were additive in effect. Their study used a longer US pulse and a much higher dose of paclitaxel than used here to generate a similar therapeutic effect [25].

US-triggered thMB drug targeting to tumors can therefore potentially be achieved on two levels. Firstly, molecular interaction occurs with a biological receptor on the tumor endothelium (VEGFR2). Secondly, physical targeting or site-specific release is promoted locally by the external delivery of an US-trigger, directed at the bound and flowing (unbound) thMBs within the tumor microenvironment. Together, these increase tumor cell uptake and/or retention of drug as seen with irinotecan thMBs. In model systems (27), targeting of MBs to a surface and exposure to US showed drug release and enhanced transport consistent with the in vivo effects observed here.

In addition to VEGFR2 targeting and a localized US-trigger, the MB structure itself was shown to play an important role in enhancing drug delivery since PET radiotracing of thMBs showed a two-fold increased concentration in blood compared with targeted liposomes alone at 1 hour post US-trigger. Our extensive analysis of tumor as well as tissue pharmacokinetics, provides insight as to how the thMB structure and the US trigger impacts on drug distribution, retention and elimination and enhances the effects of very low dose thMB delivery compared with systemic delivery of free irinotecan or VEGFR2 targeted SN38 liposomes.

The mechanism of US-mediated drug delivery is being actively studied in vitro using a variety of techniques including very high-frame rate microscopy. The Brandaris 128 ultra-high-speed-camera combined with confocal microscopy has been used to study MB oscillations and MB destruction under different US parameters as well as free drug delivery to cells [81]. Roovers et al. sectioned spheroids incubated with drug-loaded MBs and exposed to US and found that lipids from the liposomes were ‘sonoprinted’ onto the surface of the spheroids following which drug release into deeper regions was measured [82]. Recently published work from our group showed a delay in drug uptake in spheroids using drug-loaded MBs compared to free drug co-delivered with microbubbles [83] suggesting that the attached liposomes were intact following US-mediated MB destruction and prior to cellular uptake. However, further high-speed two-color camera interrogations will be required to elucidate the mechanism in real time.

Several groups have demonstrated the importance of the liposomal attachment to MBs [23, 84, 85] and direct linkage of drug loaded liposomes has been shown to improve drug delivery compared to co-delivery with free drug [23, 86]. US destruction of untargeted DOX-loaded MBs has previously been shown to enhance localized drug delivery, although the mechanisms were not determined [87]. The local energetic stimuli arising from US destruction of multiple attached and flowing thMBs in the tumor vasculature may involve physical forces (radiation, acoustic) jetting or microstreaming [88]. Theoretical and single MB experiments in vitro have suggested that oscillation of MBs may shed the liposomal payload. However, our study uses a short MB destruction pulse which is highly unlikely to cause MB oscillation alone. The thMB construct itself and the fragmentation products arising from US-triggered destruction may well underlie the altered PK properties of encapsulated drugs delivered in this way. It has been shown that in the absence of an ultrasound trigger, thMBs delivering a fluorophore could be imaged in tumors from 4 h post-injection, whereas with a trigger this accumulation occurred from the earliest imaging time point (0.5 h), irrespective of whether molecular targeting (iRGD) was present [89].

The efficacy of thMB delivery depends on MB design (e.g. size, shell properties, stability) as well as the drug itself. We initially chose irinotecan as despite its clinical application, the incidence of severe diarrhea and neutropenia can limit its use. Furthermore, the unpredictable toxicity (despite genotyping for high risk glucuronidation deactivating enzyme polymorphic variants e.g. UGT1A1 *28/*28) is an increasing cause for concern [60]. Although it has been successfully encapsulated and liposomal formulations have shown reduced toxicity [90], localized thMB delivery enables much lower systemic doses to be used and reduces the potential for dose-limiting toxicities even further. We also encapsulated SN38 for direct thMB delivery as it is up to 1000× more toxic than irinotecan and demonstrates the applicability of this platform for administration of difficult to deliver drugs. In addition, the conversion to active forms of irinotecan/SN38 (lactone) are favored in the more acidic tumor microenvironment.
and this may also contribute to the reduced toxicity seen in healthy tissues at physiological pH (where it is very rapidly converted to the carboxylated form [70]) as well as the enhanced TGI's seen with such low doses.

In traditional systemic dosing, the effectiveness of chemotherapy is determined by the tumor drug concentration and high circulating concentrations are required to obtain a therapeutic response. Liposomal formulations have the benefit of prolonged blood circulation time resulting in longer half-life, larger AUC, and slower clearance, but suffer from unspecified timing and location of drug uptake. Preclinical activity of liposomal Irinotecan has been shown to be governed by tumor deposition and intratumor prodrug conversion. A mechanistic PK model showed that concentration and time of exposure were major determinants of irinotecan efficacy in liposomal formulations and tumor permeability and carboxylesterase function limited liposomal irinotecan delivery to tumors [64]. As shown here, thMBs provide a route to achieving efficacy and overcoming these potential barriers to drug delivery in the context of irinotecan and SN38. With thMB delivery, drug concentrations delivered in a single bolus were 2 mg/kg for irinotecan and 0.4 mg/kg for SN38, far lower than those usually used systemically for irinotecan [63, 69] or for liposomal irinotecan (3.75 mg/kg) [64] and up to 8 mg/kg with liposomal SN38 [75-77]. Although we did observe some heterogeneity of response in the treatment groups, further much larger studies would be required to investigate this. However, statistically these results showed that the thMB response does not require high circulating levels of drug in plasma to achieve therapeutic effects in tumors.

ThMB delivery may prove particularly effective in some clinical settings. For example, the increasingly elderly population or those living with cancer would benefit from the low drug exposures that allow repeated delivery. In addition, there is utility for treating recurrent abdominal disease as well as metastatic CRC and hepatocellular carcinoma since the drug remains encapsulated in normal liver. Precisely focused US exposure would be necessary to achieve this.

Molecular imaging of VEGFR2 expression in patients has been proposed for antiangiogenic therapies [91] and may facilitate stratification of patients for thMB treatment. This could be achieved with contrast-enhanced ultrasound or multimodal imaging. With nearly 60 clinical trials involving MBs currently listed as open on the NIH Clinical Trials database, including 3 for treatment of gastrointestinal cancers, there is ongoing interest in the field of MBs. To facilitate translation of thMBs to the clinic, further optimization of the approach is warranted for example, by investigating alternative US parameters such as a higher MI to target central tumor areas [89] or fractionated and longer US pulses than were used in this study or a focused US beam to limit any potential for off-target US triggering. Freeze-drying of our drug loaded thMBs has also been achieved (data not shown) which will provide a facile way to clinical usage as well as aiding production at scale. The use of alternative targeting strategies such as affimers [92] or lipopeptides [93] should also be explored to reduce potential costs of treatment. Further evaluation of different liposome payloads for thMBs, thMB manufacture and theranostic clinical US systems will also aid more rapid translation of this technology for clinical use.

**Abbreviations**

ADMET: absorption, distribution, metabolism, elimination and toxicity; US: ultrasound; BFI: bioluminescent imaging; CRC: colorectal cancer; DF: deferoxamine mesylate; DPPC: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; DSPE: 1,2-distearoyl-sn-glycero-3-phosphocholine; DSPE-PEG2000: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[biotinyl (polyethylene-glycol)-2000]; EPR: enhanced permeability and retention effect; FCS: fetal calf serum; FOLFIRI: fluorouracil-leucovorin-irinotecan; HF-US: high-frequency ultrasound; HPLC: high-performance liquid chromatography; IHC: immunohistochemistry; Iri: irinotecan; LC-MS/MS: liquid chromatography tandem mass spectrometry; LOD: limit of detection; MI: mechanical index; MBs: microbubbles; MPS: mononuclear phagocytic system; NPs: nanoparticles; %ID/g: percentage injected dose per gram of tissue; PK: pharmacokinetics; PBS: phosphate buffered saline; pH2AX: phosphorylated histone H2AX; PET: positron emission tomography; SEM: standard error of the mean; SN38G: SN38 glucuronide; SMS: subtracted molecular signal; Texas Red® DHPE: Texas Red® 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium salt; TGI: tumor growth inhibition; thMBs: therapeutic microbubbles; +/-T: with or without an ultrasound trigger; Tx: treatment; US: ultrasound; VEGFR2: vascular endothelial growth factor receptor 2; Zr: zirconium.

**Acknowledgments**

The authors would like to acknowledge the EPSRC for funding (EP/100623/1, EP/K023845/1 and EP/P023266/1) and the MRC for a Confidence in Concept award and MR/L01629X. We thank Professor Mark Hull for thoughtful discussions and
collaboration. Laura E. McVeigh was funded by an EPSRC PhD Studentship (EP/L504993/1).

Supplementary Material

Supplementary figures and tables.

http://www.thno.org/v10p10973s1.pdf

Competing Interests

The authors have declared that no competing interest exists.

References

1. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. Bioeng Transl Med. 2019; 4: e10143.
2. Sindhwani S, Syed AM, Njai G, Kingston BR, Maiorino L, Rothschild J, et al. The entry of nanoparticles into solid tumours. Nat Mater. 2020; 19: 566-75.
3. de Lázaro I, Mooney DJ. A nanoparticle’s pathway into tumours. Nature Materials. 2020; 19: 486-7.
4. Liu X, Jiang J, Meng H. Transcytosis - An effective targeting strategy is complementary to “EPR effect” for pancreatic cancer nano drug delivery. Theranostics. 2019; 9: 8015-25.
5. Shi Y, van der Meel R, Chen X, Lammers T. The EPR effect and beyond: Strategies to improve tumor targeting, and cancer nanomedicine treatment efficacy. Theranostics. 2020; 10: 7921-4.
6. de Bruijn HS, Mashayekhi V, Schreurs TJL, van Driel PBAA, Strijkers GJ, et al. Acute cellular and vascular responses to photodynamic therapy using EGRF-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging. Theranostics. 2020; 10: 2436-52.
7. Garbuzenko OB, Kuzmov A, Taratula O, Pine SR, Minko T. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemotherapeutic drug delivery, and nanodevice design. Theranostics. 2019; 9: 8362-76.
8. Xu Y, Wu H, Huang J, Qian W, Mantripp AR, Ji B, et al. Probing and Enhancing Ligand-Mediated Active Targeting of Tumors Using Sub-5 nm Ultrafine Iron Oxide Nanoparticles. Theranostics. 2020; 10: 2479-94.
9. Zou Y, Wei Y, Sun Y, Bao J, Yao F, Li Z, et al. Cyclic RGD-Functionalized and Disulphide-Crosslinked Iodine-Rich Polymersomes as a Robust and Smart Theranostic Agent for Targeted CT Imaging and Chemotherapy of Tumor. Theranostics. 2019; 9: 8061-72.
10. Dubey PK, Mishra V, Jain S, Mahor S, Vyas SP. Liposomes modified with cyclic RGD peptide for tumor targeting. Journal of drug targeting. 2004; 12: 257-64.
11. Zeng YF, Wang JC, Bian DY, Zhang X, Zhang Q. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. European journal of pharmacetics and biopharmacetics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2010; 74: 45-57.
12. Wang Y, Kohane DS. External triggering and triggered targeting strategies for drug delivery. Nature Reviews Materials. 2017; 2: 17020.
13. Bowel cancer incidence statistics. Cancer Research UK; 2015-2017.
14. Nash A. National population projections: 2018-based. In: Statistics ON, editor.: Office for National Statistics; 2019.
15. Fan C-H, Ting C-Y, Liu H-L, Huang C-Y, Hsieh H-Y, Yen T-C, et al. Antiangiogenic-targeting drug loaded liposomes combined with focused ultrasound for glioma treatment. Biomaterials. 2013; 34: 2142-55.
16. Graham SM, Carlisle R, Choi JJ, Stevenson M, Shah AR, Myers RS, et al. Intracavitary unmanned delivery, nanotechnology, tumor -receptor targeting, chemo - and gene therapy. Theranostics. 2019; 9: 8362-76.
17. Nash A, Reising LO, Nedderman DM, Fulford AD, Uhlrik MT, Benjamin LE, et al. Heterogeneity of Vascular Endothelial Growth Factor Receptor 1, 2, 3 in Primary Human Colorectal Carcinoma. Anticancer Res. 2016; 36: 2683-96.
18. Smith DR, Baker DJ, James NH, Ratcliffe K, Jenkins M, Ashston SE, et al. Intracavitary unmanned delivery, nanotechnology, tumor -receptor targeting, chemo - and gene therapy. Theranostics. 2019; 9: 8362-76.
19. Lin CY, Huang YL, Li JR, Chang FH, Lin WL. Effects of focused ultrasound and microbubbles on the vascular permeability of nanoparticles delivered into mouse tumors. Ultrasound Med Biol. 2010; 36: 1460-9.
20. O'Neill BE, Vo H, Angstadt M, Li KP, Quinn T, Frenkel V. Pulsed high intensity focused ultrasound mediated nanoparticle delivery: mechanisms and efficacy in murine muscle. Ultrasound Med Biol. 2009; 35: 416-24.
21. Drnecvski G, Koutoupiou S, Bjarne T, Hoem D, Schijit J, Jgerts BT, et al. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. J Control Release. 2016; 214: 172-81.
22. Wang Y, Li Y, Yan K, Shen L, Yang W, Gong J, et al. Clinical study of ultrasound and microbubbles for enhancing chemotherapeutic sensitivity of malignant tumors in digestive system. Chin J Cancer Res. 2018; 30: 553-63.
23. Cool SK, Geers B, Roels S, Stremersch S, Vanderprenen K, Saunders JH, et al. Coupling of drug containing liposomes to microbubbles improves ultrasound triggered drug delivery in mice. J Control Release. 2013; 172: 885-97.
24. Escoffe JM, Mannaris C, Geers B, Novell A, Lentacker L, Averkiou M, et al. Doxorubicin liposome-loaded microbubbles for contrast imaging and ultrasound-triggered drug delivery. IEEE transactions on ultrasonics, ferroelectrics, and frequency control. 2013; 60: 78-87.
25. Zhang J, Wang S, Deng Z, Li L, Tan G, Liu X, et al. Ultrasonographic -Triggered Drug Delivery for Breast Tumor Therapy Through iRGD -Targeted Paclitaxel -Loaded Liposome-Microbubble Complexes. J Biomed Nanotechnol. 2018; 14: 1384-95.
26. Luan Y, Lajoiein G, Gelderblom E, Skachkov I, van der Steen AF, Vos HJ, et al. Lipid shedding from single oscillating microbubbles. Ultrasound Med Biol. 2014; 40: 1834-46.
27. Lajoiein G, Luan Y, Gelderblom E, Dollet B, Mastik F, Dewitte H, et al. Non-spherical oscillations drive the ultrasound-mediated release from targeted microbubbles. Communications Physics. 2018; 1: 22.
28. Marmontart P, Hilgenfeldt S. Controlled vesicle deformation and lysis by single-oscillating bubbles. Nature. 2005; 435: 166-75.
29. Anderson CR, Hu X, Zhang H, Tlaoca J, Declleves AE, Houghtaling R, et al. Ultrasonic molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent. Invest Radiol. 2011; 46: 215-24.
30. Warran JM, Sorace AG, Saini R, Umprey HR, Zinn KR, Hoyt K. A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature. J Ultrasound Med. 2011; 30: 921-31.
31. Willmann JK, Paulmurugan R, Chen K, Ghysens O, Rodriguez-Porc el M, Lutz AM, et al. US Imaging of Tumor Angiogenesis with Microbubbles Targeted to Vascular Endothelial Growth Factor Receptor Type 2 in Mice2. Radiology. 2008; 246: 508-18.
32. Zhang Z, Yao J. Preparation of irinotecan-loaded folate-targeted liposome for tumor targeting delivery and its antitumor activity. AAPS PharmSciTech. 2012; 13: 802-10.
33. Nasir A, Reising LO, Nedderman DM, Fulford AD, Uhlrik MT, Benjamin LE, et al. Heterogeneity of Vascular Endothelial Growth Factor Receptor 1, 2, 3 in Primary Human Colorectal Carcinoma. Anticancer Res. 2016; 36: 2683-96.
34. Smith DR, Baker DJ, James NH, Ratcliffe K, Jenkins M, Ashston SE, et al. Intracavitary unmanned delivery, nanotechnology, tumor -receptor targeting, chemo - and gene therapy. Theranostics. 2019; 9: 8362-76.
35. Willmann JK, Paulmurugan R, Chen K, Ghysens O, Rodriguez-Porcel M, Lutz AM, et al. US Imaging of Tumor Angiogenesis with Microbubbles Targeted to Vascular Endothelial Growth Factor Receptor Type 2 in Mice2. Radiology. 2008; 246: 508-18.
36. Eschbach RS, Cleveri D-A, Hirmer-Eppeneder H, Ingrisch M, Moser M, Schuster J, et al. Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemestral Validation. PLOS ONE. 2017; 12: e0169323.
37. Smeenge M, Tranquart F, Mannerts CK, de Reijke TM, van de Vijver MJ, de Langen MP, et al. First-in-Human Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First -in-Human Results. Journal of Clinical Oncology. 2017; 35: 5469-75.
38. Willmann JK, Bonomo L, Testa AC, Rinaldi P, Rindi G, Vallerio KS, et al. Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy. Theranostics. 2018; 8: 141-55.
39. Robert J, Rivory L. Pharmacology of irinotecan. Drugs Today (Barc). 1998; 34: 777-803.
40. Ramesh M, Aalavhati P, Srinivas NR. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical
pharmacology perspectives. Biomedical Chromatography. 2010; 24: 104-23.

42. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1983; 43: 1722-25.

43. Peyman SA, Abou-Saleh RH, McLaughlan JR, Ingram N, Johnson BR, Critchley K, et al. Expanding 3D geometry for enhanced on-chip microbubble production and single step formation of liposome modified microbubbles. Lab Chip. 2012; 12: 4544-52.

44. Abou-Saleh RH, Peyman SA, Johnson BR, Marston G, Ingram N, Bushby R, et al. The influence of intercalating perfluorooctane into lipid shells on nano and microbubble stability. Soft Matter. 2016. McLaughlan J, Ingram N, Smith PR, Harput S, Coletta PL, Evans S, et al.

45. McLaughlan JR, Ingram N, Northwood EL, Perry SL, Marston G, Snowden H, Taylor JC, et al. Reduced type II interleukin-4 receptor signalling drives initiation but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human case-control epidemiological observations. Carcinogenesis. 2013; 34: 2341-9.

46. Abdelrahman A, Marston G, Hull MA, Markham AF, Jones FP, Evans JA, et al. High-frequency ultrasound for in vivo measurement of colon wall thickness. Ultrasound Med Biol. 2012; 38: 432-42.

47. Kheiroramoon A, Kruse DE, Qin S, Watson KE, Lai CY, Young LJ, et al. Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system. J Control Release. 2010; 141: 128-36.

48. Messerer CL, Ramsay EC, Waterhouse D, Ng K, Simms EM, Harasym N, et al. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res. 2004; 10: 6638-49.

49. Ahmad I, Zhang JA. Pharmacologically active lipid based formulation of SN-38. Google Patents; 2005.

50. Seo JW, Mahakian LM, Tam S, Qin S, Ingham ES, Meares CF, et al. The pharmacokinetics of ZR-89 labeled liposomes over extended periods in a murine tumor model. Nucl Med Biol. 2015; 42: 155-63.

51. Church CC. Frequency, pulse length, and the mechanical index. Acoust Res Lett Onl. 2005; 6: 162-8.

52. Ramesh M, Ahlawat P, Srinivas NR. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010; 24: 104-23.

53. Hawcroft G, Volpato M, Marston G, Ingram N, Perry SL, Cockbain AJ, et al. The omega-3 polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MC-26 colorectal cancer cell liver metastasis via inhibition of PGE2-dependent cell motility. British journal of pharmacology. 2012; 166: 1274-37.

54. Wright AI, Grabsch HI, Treanor DE. RandomSpot: A web-based tool for quantification of bioactivity from whole-body biodistribution with dynamic micro-PET in mice. Lab Chip. 2011; 11: 2122-31.

55. Le S, Chien PY, Sheikh S, Zhang A, Ali S, Ahmad I. Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice. Anticancer Drugs. 2004; 15: 773-8.

56. Zhang JA, Xuan T, Parmar M, Ma L, Uguwu S, Ali S, et al. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm. 2004; 270: 93-107.

57. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002; 2: 750-63.

58. Willmann JK, Cheng Z, Davis C, Lutz AM, Schipper ML, Niels en CH, et al. Tumor microbubble populations using chirp excitation. IEEE transactions on ultrasonics, ferroelectrics, and frequency control. 2013; 60: 2531-20.

59. Ali MA, Noguchi S, Iwao Y, Oka T, Ito A. Preparation and Characterization of Liposome-Loaded Microbubble Populations for Subharmonic Imaging. Ultrasound Med Biol. 2017; 43: 346-56.

60. Ingram N, Northwood EL, Perry SL, Marston G, Snowden H, Taylor JC, et al. Reduced type II interleukin-4 receptor signalling drives initiation but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human case-control epidemiological observations. Carcinogenesis. 2013; 34: 2341-9.

61. Abdelrahman A, Marston G, Hull MA, Markham AF, Jones FP, Evans JA, et al. High-frequency ultrasound for in vivo measurement of colon wall thickness. Ultrasound Med Biol. 2012; 38: 432-42.

62. Kheiroramoon A, Kruse DE, Qin S, Watson KE, Lai CY, Young LJ, et al. Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system. J Control Release. 2010; 141: 128-36.

63. Messerer CL, Ramsay EC, Waterhouse D, Ng K, Simms EM, Harasym N, et al. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res. 2004; 10: 6638-49.

64. Ahmad I, Zhang JA. Pharmacologically active lipid based formulation of SN-38. Google Patents; 2005.

65. Seo JW, Mahakian LM, Tam S, Qin S, Ingham ES, Meares CF, et al. The pharmacokinetics of ZR-89 labeled liposomes over extended periods in a murine tumor model. Nucl Med Biol. 2015; 42: 155-63.

66. Church CC. Frequency, pulse length, and the mechanical index. Acoust Res Lett Onl. 2005; 6: 162-8.

67. Ramesh M, Ahlawat P, Srinivas NR. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010; 24: 104-23.

68. Hawcroft G, Volpato M, Marston G, Ingram N, Perry SL, Cockbain AJ, et al. The omega-3 polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MC-26 colorectal cancer cell liver metastasis via inhibition of PGE2-dependent cell motility. British journal of pharmacology. 2012; 166: 1274-37.

69. Wright AI, Grabsch HI, Treanor DE. RandomSpot: A web-based tool for systematic random sampling of virtual slides. J Pathol Inform. 2015; 6: 8.

70. Winter J, Kneitz H, Brocker EB. Blood vessel density in Basal cell carcinomas and benign trichogenic tumors as a marker for differential diagnosis in dermatopathology. J Skin Cancer. 2011. 2011: 241382.

71. Matthais D, Foukas PG, Kefala M, Hountis P, Tryptisianis G, Panayiotides IG, et al. In-vivo expression detected by immunohistochemistry correlates with prognosis in early operable non-small cell lung cancer. Onco Targets and therapy. 2012; 5: 309-14.

72. Ruffrock AC, Johnson DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001; 23: 291-9.

73. Ratain MJ. Irinotecan dosing: does the CPT in CPT-11 stand for 'Can't Predict Toxicity'? J Clin Oncol. 2002; 20: 7-8.

74. O’Farrell AC, Shnyder SD, Marston G, Coletta PL, Gill JH. Non-invasive microbubble production and single step formation of liposome modified microbubbles. Lab Chip. 2012; 12: 4544-52.

75. Chojamiets B, Nagamura Y, Nakajima K, Kawaiyabashi T, Miyamoto S, Tachibana K, et al. Metronomic irinotecan chemotherapy combined with ultrasound irradiation for a human uterine sarcoma xenograft. Cancer Science. 2011; 102: 452-9.

76. Kalra AV, Kim J, Klinz SG, Paz N, Cain J, Drummond DC, et al. Pharmacological activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodruk conversion. Cancer Res. 2014; 74: 7003-13.

77. Caron WP, Lay JC, Fong AM, La-Beck NM, Kumar P, Newman SE, et al. Translational studies of phenotypic probes for the monoclonal

http://www.thno.org
88. Kooiman K, Vos HJ, Versluis M, de Jong N. Acoustic behavior of microbubbles and implications for drug delivery. Adv Drug Deliv Rev. 2014; 72: 28-48.
89. Eggen S, Fagerland SM, Morch Y, Hansen R, Sovik K, Berg S, et al. Ultrasound-enhanced drug delivery in prostate cancer xenografts by nanoparticles stabilizing microbubbles. J Control Release. 2014; 187: 39-49.
90. Pelzer U, Blanc JF, Melisi D, Cubillo A, Von Hoff DD, Wang-Gillam A, et al. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWIST analysis. Br J Cancer. 2017; 116: 1247-53.
91. Mitran B, Guler R, Roche FP, Lindstrom E, Selvaraju RK, Fleetwood F, et al. Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model. Theranostics. 2018; 8: 4462-76.
92. Tiede C, Bedford R, Heseltine SJ, Smith G, Wijetunga I, Ross R, et al. Affimer proteins are versatile and renewable affinity reagents. eLife. 2017; 6: e24903.
93. Pochon S, Tardy I, Bussat P, Bettinger T, Brochet J, von Wronsiki M, et al. BR55: A Lipopeptide-Based VEGFR2-Targeted Ultrasound Contrast Agent for Molecular Imaging of Angiogenesis. 2010; 45: 89-95.